keyword
https://read.qxmd.com/read/38718270/prevalence-of-multi-drug-resistant-bacteria-in-intensive-care-units-at-tripoli-university-hospital-tripoli-libya
#1
JOURNAL ARTICLE
Khaled Ibrahim, Dalal Thwood, Hajer ELgheriani, Mohamed Salem, Zaynab Elgadiym, Ahmed Zaghdani, Inas Alhudiri, Abdulraouf Habibi, Abdurrezagh Elfahem, Saadeddin Belaid, Otman Ermithi, Mahmoud Almaghrabi, Abubaker ELmaryul, Suad Almadah, Abdunnabi Rayes, Salah Edin El Meshri, Allaaeddin El Salabi, Adam Elzagheid
Among hospitalized patients worldwide, infections caused by multidrug-resistant (MDR) bacteria are a major cause of morbidity and mortality. This study aimed to isolate MDR bacteria from five intensive care units (ICUs) at Tripoli University Hospital (TUH). A prospective cross-sectional study was conducted over a seven-month period (September 2022 to March 2023) across five ICUs at TUH. A total of 197 swabs were collected from Patients', healthcare workers' and ICUs equipment. Samples collected from patients were nasal swabs, oral cavity swabs, hand swabs, sputum specimens, skin swabs, umbilical venous catheter swabs, and around cannula...
December 31, 2024: Libyan Journal of Medicine
https://read.qxmd.com/read/38697811/beyond-resistance-assessing-sulbactam-durlobactam-s-role-in-today-s-clinical-landscape
#2
EDITORIAL
Ahmad Z Al Meslamani
No abstract text is available yet for this article.
May 2, 2024: Expert Review of Anti-infective Therapy
https://read.qxmd.com/read/38697579/intravenous-fosfomycin-for-treatment-of-severe-infections-caused-by-carbapenem-resistant-acinetobacter-baumannii-a-multicenter-clinical-experience
#3
JOURNAL ARTICLE
Alessandro Russo, Sara Palma Gullì, Alessandro D'Avino, Cristian Borrazzo, Novella Carannante, Francesco Cogliati Dezza, Sara Covino, Giorgio Polistina, Giuseppe Fiorentino, Enrico Maria Trecarichi, Claudio Maria Mastroianni, Carlo Torti, Alessandra Oliva
BACKGROUND: severe infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have been increasingly reported over the past few years. Many in vivo and in vitro studies suggest a possible role of intravenous fosfomycin for the treatment of CRAB infections. METHODS: this multicenter, retrospective study included patients treated with intravenous fosfomycin for severe infections caused by CRAB admitted consecutively from December 2017 to December 2022 in four Hospitals in Italy...
April 30, 2024: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/38688353/treatment-of-infections-caused-by-multidrug-resistant-gram-negative-bacilli-a-practical-approach-by-the-italian-simit-and-french-spilf-societies-of-infectious-diseases
#4
JOURNAL ARTICLE
Marianna Meschiari, Antoine Asquier-Khati, Giusy Tiseo, David Luque-Paz, Rita Murri, David Boutoille, Marco Falcone, Cristina Mussini, Pierre Tattevin
INTRODUCTION: The emergence of multidrug-resistant Gram-negative bacilli, and the development of new antibiotics have complexified selection of optimal regimens. International guidelines are valuable tools, though limited by scarcity of high-quality randomized trials in many situations. METHODS: A panel of experts from the French and Italian Societies of Infectious Diseases aimed to address unresolved issues in clinical practice based on their experience, updated literature review, and open discussions...
April 28, 2024: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/38676856/evolution-control-and-success-of-combination-therapy-with-ampicilin-sulbactam-ceftazidime-avibactam-during-a-carbapenem-resistant-acinetobacter-baumannii-outbreak-in-burn-intensive-care-unit
#5
JOURNAL ARTICLE
Emmanuel Dudoignon, Francois Caméléna, Matthieu Lafaurie, Benjamin Deniau, Maité Chaussard, Maxime Coutrot, Lucie Guillemet, Alexandru Cupaciu, Alexandre Pharaboz, Louis Boutin, Mourad Benyamina, Marc Chaouat, Maurice Mimoun, Manel Merimèche, Alexandre Mebazaa, Benoit Plaud, Béatrice Berçot, François Dépret, Guillaume Mellon
We present our findings on interpatient transmission, epidemic control measures, and the outcomes of a series of ten critically ill burn patients who were either colonized or infected with carbapenem-resistant Acinetobacter baumannii (CRAB). None of the five infected patients achieved clinical cure, and all experienced relapses. Microbiological failure was observed in 40% of the infected patients. The isolated CRAB strains were found to carry blaOXA-23 and armA resistance genes. Despite the lack of clinical cure, all five infected patients survived and were discharged from the Burn Intensive Care Unit...
April 27, 2024: European Journal of Clinical Microbiology & Infectious Diseases
https://read.qxmd.com/read/38656082/molecular-epidemiology-and-clinical-significance-of-carbapenemase-genes-among-carbapenem-resistant-acinetobacter-baumannii-isolates-in-southern-poland
#6
JOURNAL ARTICLE
Piotr A Serwacki, Dariusz A Hareza, Anna Kujawska, Anna Pałka, Estera Jachowicz-Matczak, Agata Rybka-Grymek, Wioletta Świątek-Kwapniewska, Iwona Pawłowska, Zofia Gniadek, Karolina Gutkowska, Mateusz Gajda, Jadwiga Wójkowska-Mach
INTRODUCTION: The complex interplay between Acinetobacter spp., patients, and the environment has made it increasingly difficult to optimally treat patients infected with Acinetobacter spp., mainly due to rising antimicrobial resistance and challenges with surveillance. OBJECTIVES: This study evaluated carbapenem-resistance Acinetobacter baumannii (CRAB) isolates to determine their resistance profiles and the presence of specific β-lactamase enzymes to inform the use of CRAB surveillance upon hospital admission and regional empiric antibiotic therapies...
April 23, 2024: Polish Archives of Internal Medicine
https://read.qxmd.com/read/38651885/first-report-of-the-chromosomal-integration-of-carbapenemase-gene-bla-imp-19-in-acinetobacter-baumannii-ab322-the-legacy-of-integron-in-phage-plasmid
#7
JOURNAL ARTICLE
Yung-Luen Shih, Carl Jay Ballena Bregente, Pek Kee Chen, Tran Thi Dieu Thuy, Yu-Chen Chen, Han-Yueh Kuo, Hsu-Feng Lu, Cheng-Yen Kao
UNLABELLED: Integration of carbapenemase gene bla IMP into the chromosome of carbapenem-resistant Acinetobacter baumannii (CRAB) has not been reported. The aim of this study was to explore the genomic characteristics of CRAB AB322 isolated from a Taiwanese patient diagnosed with bacteremia in 2011, whose chromosome harbors bla IMP-19 . Disk diffusion and broth microdilution were employed to analyze the antimicrobial susceptibility of AB322 to 14 antimicrobials. Nanopore whole-genome sequencing platform was utilized for AB322 genome sequencing, and conjugation was further performed to investigate the transferability of bla IMP-19 to amikacin-resistant A...
April 23, 2024: Microbiology Spectrum
https://read.qxmd.com/read/38630890/successful-treatment-of-carbapenem-resistant-acinetobacter-baumannii-meningitis-with-sulbactam-durlobactam
#8
JOURNAL ARTICLE
Pranita D Tamma, Shanan Immel, Sara M Karaba, Caitlin L Soto, Rick Conzemius, Emily Gisriel, Tsigereda Tekle, Haley Stambaugh, Emily Johnson, Jeffrey A Tornheim, Patricia J Simner
BACKGROUND: The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges. METHODS: We report the case of a 42-year-old woman with CRAB meningitis who experienced persistently positive cerebrospinal fluid (CSF) cultures for 13 days despite treatment with high-dose ampicillin-sulbactam and cefiderocol. On day 13, she was transitioned to sulbactam-durlobactam and meropenem; four subsequent CSF cultures remained negative...
April 17, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38595956/clinical-outcomes-for-patients-with-monomicrobial-vs-polymicrobial-acinetobacter-baumannii-calcoaceticus-complex-infections-treated-with-sulbactam-durlobactam-or-colistin-a-subset-analysis-from-a-phase-3-clinical-trial
#9
JOURNAL ARTICLE
Sarah M McLeod, Alita A Miller, Khurram Rana, David Altarac, Samir H Moussa, Adam B Shapiro
BACKGROUND: In a previous study, the efficacy and safety of sulbactam-durlobactam vs colistin for the treatment of patients with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections were evaluated in a randomized controlled phase 3 trial. Both arms were dosed on a background of imipenem-cilastatin to treat coinfecting gram-negative pathogens. Thirty-six percent of infections in the primary efficacy population were polymicrobial. METHODS: A subset analysis was performed to compare clinical and microbiological outcomes at test of cure (7 ± 2 days after the last dose) for patients with monomicrobial and polymicrobial CRABC infections...
April 2024: Open Forum Infectious Diseases
https://read.qxmd.com/read/38594467/in-vitro-activity-of-antibiotics-potentially-effective-against-difficult-to-treat-strains-of-gram-negative-rods-retrospective-study
#10
JOURNAL ARTICLE
Gabriela Kroneislová, Jan Závora, Vanda Gabriela Adámková, Anna Rýdlová, Václava Adámková
Bacterial resistance surveillance is one of the main outputs of microbiological laboratories and its results are important part of antimicrobial stewardship (AMS). In this study, the susceptibility of specific bacteria to selected antimicrobial agents was tested. The susceptibility of 90 unique isolates of pathogens of critical priority obtained from clinically valid samples of ICU patients in 2017-2021 was tested. 50% of these fulfilled difficult-to-treat resistance (DTR) criteria and 50% were susceptible to all antibiotics included in the definition...
April 9, 2024: Scientific Reports
https://read.qxmd.com/read/38567976/characterization-of-acinetobacter-baumannii-calcoaceticus-complex-isolates-and-microbiological-outcome-for-patients-treated-with-sulbactam-durlobactam-in-a-phase-3-trial-attack
#11
JOURNAL ARTICLE
Alita A Miller, Samir H Moussa, Sarah M McLeod
Acinetobacter baumannii-calcoaceticu s complex (ABC) causes severe, difficult-to-treat infections that are frequently antibiotic resistant. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat ABC infections, including those caused by multidrug-resistant strains. In a global, pathogen-specific, randomized, controlled phase 3 trial (ATTACK), the efficacy and safety of SUL-DUR were compared to colistin, both dosed with imipenem-cilastatin as background therapy, in patients with serious infections caused by carbapenem-resistant ABC...
April 3, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38534696/current-therapeutic-approaches-for-multidrug-resistant-and-extensively-drug-resistant-acinetobacter-baumannii-infections
#12
REVIEW
Petros Rafailidis, Periklis Panagopoulos, Christos Koutserimpas, George Samonis
The treatment of Acinetobacter baumannii infections remains a challenge for physicians worldwide in the 21st century. The bacterium possesses a multitude of mechanisms to escape the human immune system. The consequences of A. baumannii infections on morbidity and mortality, as well on financial resources, remain dire. Furthermore, A. baumannii superinfections have also occurred during the COVID-19 pandemic. While prevention is important, the antibiotic armamentarium remains the most essential factor for the treatment of these infections...
March 15, 2024: Antibiotics
https://read.qxmd.com/read/38501368/in-vitro-activity-of-apramycin-ebl-1003-in-combination-with-colistin-meropenem-minocycline-or-sulbactam-against-xdr-pdr-acinetobacter-baumannii-isolates-from-greece
#13
JOURNAL ARTICLE
I Galani, M Souli, D Katsala, I Karaiskos, H Giamarellou, A Antoniadou
OBJECTIVES: To evaluate the in vitro activity of the combination of apramycin with colistin, meropenem, minocycline or sulbactam, against some well-characterized XDR Acinetobacter baumannii clinical isolates from Greece, to understand how apramycin can be best incorporated into clinical practice and optimize effectiveness. METHODS: In vitro interactions of apramycin (0.5×, 1× and 2× the MIC value) with colistin (2 mg/L), meropenem (30 mg/L), minocycline (3...
March 19, 2024: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/38496545/hetero-antagonism-of-avibactam-and-sulbactam-with-cefiderocol-in-carbapenem-resistant-acinetobacter-spp
#14
Olivia Wong, Vyanka Mezcord, Christina Lopez, German Matias Traglia, Fernando Pasteran, Marisel R Tuttobene, Alejandra Corso, Marcelo E Tolmasky, Robert A Bonomo, María Soledad Ramirez
The emergence of Gram-negative bacteria resistant to multiple antibiotics, particularly carbapenem-resistant (CR) Acinetobacter strains, poses a significant threat globally. Despite efforts to develop new antimicrobial therapies, limited progress has been made, with only two drugs-cefiderocol and sulbactam-durlobactam-showing promise for CR- Acinetobacter infections. Cefiderocol, a siderophore cephalosporin, demonstrates promising efficacy in the treatment of Gram-negative infections. However, resistance to cefiderocol has been reported in A...
March 4, 2024: bioRxiv
https://read.qxmd.com/read/38483164/-in-vitro-activity-of-cefiderocol-against-european-pseudomonas-aeruginosa-and-acinetobacter-spp-including-isolates-resistant-to-meropenem-and-recent-%C3%AE-lactam-%C3%AE-lactamase-inhibitor-combinations
#15
JOURNAL ARTICLE
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D Perry, Mathias W Pletz, Stefania Stefani, Ian Morrissey, Christopher Longshaw
UNLABELLED: Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. represent major threats and have few approved therapeutic options. Non-‍fermenting Gram-negative isolates were collected from hospitalized inpatients from 49 sites in 6 European countries between 01 January 2020 and 31 December 2020 and underwent susceptibility testing against cefiderocol and β-lactam/β-lactamase inhibitor combinations. Meropenem-resistant (MIC >8 mg/L), cefiderocol-susceptible isolates were analyzed by PCR, and cefiderocol-resistant isolates were analyzed by whole-genome sequencing to identify resistance mechanisms...
March 14, 2024: Microbiology Spectrum
https://read.qxmd.com/read/38469762/nomogram-based-on-clinical-characteristics-to-predict-28-day-mortality-among-patients-with-crab-bsi
#16
JOURNAL ARTICLE
Jiong Xiong, Xiaoqian Zhou, Yan Tang
BACKGROUND: The drug resistance of carbapenem-resistant Acinetobacter baumannii bloodstream infections (CRAB-BSI), especially hospital-acquired infections, has promoted their rapid and vast spread. It is necessary to use reliable methods to establish better prediction models. According to Cox proportional hazards regression, a nomogram was established. METHODS: A retrospective cohort study among patients who were diagnosed with CRAB-BSI was performed from January 2020 to December 2022...
March 1, 2024: Clinical Laboratory
https://read.qxmd.com/read/38450331/characteristics-and-susceptibility-pattern-of-catheter-associated-urinary-tract-infections-cauti-bacteria-in-indonesia-a-study-in-a-national-reference-hospital-of-sumatra-region-2020-2021
#17
JOURNAL ARTICLE
Muhammad A Perdana, Dian D Wahyuni, Rina Yunita
Catheter-associated urinary tract infection (CAUTI) is defined as a urinary tract infection associated with catheter placement for more than two consecutive days. Hence, antibiotic resistance in the context of CAUTIs represents a substantial challenge. The aim of this study was to present the characteristics of patients with CAUTI and the susceptibility pattern of CAUTI bacteria in the national reference hospital of the Sumatra region of Indonesia. A cross-sectional study was conducted at H. Adam Malik General Hospital, Medan, Indonesia, from 2020 to 2021, using a total sampling...
December 2023: Narra J
https://read.qxmd.com/read/38426849/sulbactam-durlobactam-a-%C3%AE-lactam-%C3%AE-lactamase-inhibitor-combination-targeting-acinetobacter-baumannii
#18
REVIEW
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years of age and older. Sulbactam is a penicillin derivative with antibacterial activity against Acinetobacter but is prone to hydrolysis by β-lactamases encoded by contemporary isolates...
March 1, 2024: Future Microbiology
https://read.qxmd.com/read/38417705/international-guidelines-for-the-treatment-of-carbapenem-resistant-gram-negative-bacilli-infections-a-comparison-and-evaluation
#19
JOURNAL ARTICLE
Chuhui Wang, Chuqi Bai, Keyu Chen, Qian Du, Shiqi Cheng, Xiaoyan Zeng, Yan Wang, Yalin Dong
OBJECTIVES: This study aimed to appraise clinical practice guidelines (CPGs) for the treatment of carbapenem-resistant Gram-negative bacilli (CRGNB) infections and to summarize the recommendations. METHODS: A systematic search of the literature published from January 2012 to March 2023 was undertaken to identify CPGs related to CRGNB infections treatment. The methodological and reporting quality of eligible CPGs were assessed using six domains of the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool and seven domains of the Reporting Items for practice Guidelines in HealThcare (RIGHT) checklist...
February 26, 2024: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/38358170/outbreak-of-multidrug-resistant-acinetobacter-baumannii-in-a-tertiary-health-center-from-northwestern-nigeria
#20
JOURNAL ARTICLE
Yahaya Mohammed, Abubakar Sadiq Muhammad, Sabitu Muhammad Zainu, Ahmed Kolawole Jimoh, Ahmed Olowo-Okere, Ibrahim Abayomi Ogunyinka, Jibril Abubakar, Khadijah Muhammad Dada, Oloche Emmanuel Egbe, Salma Muhammad Galalain
BACKGROUND: In spite of its global notoriety and WHO alarm, Acinetobacter baumannii is still an understudied critical-priority pathobiont in Nigeria. We characterized its antimicrobial susceptibility profile and resistance genes during an outbreak. MATERIALS AND METHODS: This cross-sectional study involved collection of patients' urine samples and swabs from unit staff's hands and ward environments for the identification of A. baumannii strains using standard morphologic and biochemical methods...
2024: Annals of African Medicine
keyword
keyword
57609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.